Back to search
FDAFDA · Food and drugs·Recall number D-0104-2021

clomiPRAMINE Hydrochloride Capsules USP, 50 mg, 30-count bottle, Rx Only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD NDC 59746-711-30

Published December 2, 2020 · Recall initiated: November 6, 2020

Summary

FDA records drug Class II recall D-0104-2021, published December 2, 2020 and initiated November 6, 2020. Recalling firm: Jubilant Cadista Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 4,416 bottles; Lot: Lot# 20P0141, exp. date 02/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Tablet/Capsule Specification

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Jubilant Cadista Pharmaceuticals, Inc.
Distributor
Product was distributed nationwide.
Lot
Lot# 20P0141, exp. date 02/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was clomiPRAMINE Hydrochloride Capsules USP, 50 mg, 30-count bottle, Rx Only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD NDC 59746-711-30 recalled?

Yes. FDA published recall D-0104-2021 on December 2, 2020. Reported hazard: Failed Tablet/Capsule Specification

What should I do if I have this product?

Voluntary: Firm initiated · Letter